Literature DB >> 3911593

Strategies for treating autoimmune disease with monoclonal antibodies.

D Wofsy.   

Abstract

There is no safe and reliable therapy for most serious autoimmune diseases, such as systemic lupus erythematosus. Severe cases usually require treatment with corticosteroids or cytotoxic drugs or both, which frequently provide inadequate disease control and can cause serious complications. These therapies are not restricted in their effects to cells of the immune system, but rather have a broad range of toxic effects on cells throughout the body. The development of monoclonal antibodies has led to new therapeutic strategies through which treatment can be focused more directly on specific cells (and functions) of the immune system. These strategies have already produced promising results in animal models for several important human autoimmune diseases. We will know soon whether treatment with monoclonal antibodies will be effective in persons with autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3911593      PMCID: PMC1306490     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  27 in total

1.  Treatment of intractable lupus nephritis with total lymphoid irradiation.

Authors:  S Strober; E Field; R T Hoppe; B L Kotzin; O Shemesh; E Engleman; J C Ross; B D Myers
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

2.  Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo.

Authors:  S P Cobbold; A Jayasuriya; A Nash; T D Prospero; H Waldmann
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

3.  Efficacy of total lymphoid irradiation in intractable rheumatoid arthritis. A double-blind, randomized trial.

Authors:  S Strober; A Tanay; E Field; R T Hoppe; A Calin; E G Engleman; B Kotzin; B W Brown; H S Kaplan
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

4.  In vivo effects of antibodies against a high frequency idiotype of anti-DNA antibodies in MRL mice.

Authors:  D Teitelbaum; J Rauch; B D Stollar; R S Schwartz
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

5.  In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D A Hafler; D A Fox; M E Manning; S F Schlossman; E L Reinherz; H L Weiner
Journal:  N Engl J Med       Date:  1985-05-30       Impact factor: 91.245

Review 6.  NIH conference. Systemic lupus erythematosus: insights from animal models.

Authors:  A D Steinberg; E S Raveché; C A Laskin; H R Smith; T Santoro; M L Miller; P H Plotz
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

7.  Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice.

Authors:  D Wofsy; D C Mayes; J Woodcock; W E Seaman
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

8.  Treatment of murine lupus with monoclonal anti-T cell antibody.

Authors:  D Wofsy; J A Ledbetter; P L Hendler; W E Seaman
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

9.  Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker.

Authors:  M K Waldor; S Sriram; R Hardy; L A Herzenberg; L A Herzenberg; L Lanier; M Lim; L Steinman
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

10.  Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.

Authors:  D Wofsy; W E Seaman
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

View more
  6 in total

1.  ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells.

Authors:  Chuda Chittasupho; Sheng-Xue Xie; Abdulgader Baoum; Tatyana Yakovleva; Teruna J Siahaan; Cory J Berkland
Journal:  Eur J Pharm Sci       Date:  2009-02-27       Impact factor: 4.384

Review 2.  Monoclonal antibodies as magic bullets.

Authors:  F M Brodsky
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

3.  cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells.

Authors:  Chuda Chittasupho; Prakash Manikwar; Jeffrey P Krise; Teruna J Siahaan; Cory Berkland
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

4.  Monoclonal antibodies and immobilized antibodies. Patents and literature.

Authors:  R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1987-06       Impact factor: 2.926

5.  New approaches to treating systemic lupus erythematosus.

Authors:  D Wofsy
Journal:  West J Med       Date:  1987-08

Review 6.  The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance.

Authors:  Lilly Stahl; Anna Duenkel; Nadja Hilger; Uta Sandy Tretbar; Stephan Fricke
Journal:  Front Immunol       Date:  2019-05-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.